title: [Clinical development and future perspective of biological agents].
abstract: Biological agents targeting against a series of pro-inflammatory cytokines have provided an enormous impact on the therapeutic management on inflammatory disorders such as rheumatoid arthritis. Clinical development of biological agents in Japan, particularly, TNF inhibitors, has been reviewed in this paper, and future perspective is discussed.
authors.affiliation: Division of Rheumatology, Department of Internal Medicine, Saitama Medical Center, Saitama Medical University.
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Takeuchi
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018501:Antirheumatic Agents; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000209:etiology; D016207:Cytokines / Q000276:immunology / Q000502:physiology; D015195:Drug Design; D006801:Humans; D018836:Inflammation Mediators / Q000276:immunology / Q000502:physiology; D000069285:Infliximab; D007375:Interleukin-1; D015850:Interleukin-6; D007564:Japan; D047889:Receptors, Tumor Necrosis Factor, Type II; D014409:Tumor Necrosis Factor-alpha
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D016207:Cytokines; D018836:Inflammation Mediators; D007375:Interleukin-1; D015850:Interleukin-6; D047889:Receptors, Tumor Necrosis Factor, Type II; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab